| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
7-Hydroxy-4-methyl-8-nitrocoumarin does not have a specific well-defined biological target. As a coumarin derivative, it is known to exhibit antibacterial and antioxidant activities. The compound's mechanism of action is believed to involve interactions with bacterial enzymes or cellular components, leading to inhibition of bacterial growth. Its antioxidant activity is attributed to the presence of the hydroxyl group, which can scavenge free radicals. The compound is used as a research tool to study the biological activities of coumarin derivatives.
|
|---|---|
| ln Vitro |
In vitro, 7-Hydroxy-4-methyl-8-nitrocoumarin demonstrates antibacterial activity against Staphylococcus aureus and Escherichia coli. The compound also exhibits antioxidant activity. These in vitro activities make it a subject of research for potential antimicrobial and antioxidant applications. The compound's activity is attributed to its unique combination of functional groups on the coumarin core. Further studies are needed to fully characterize its in vitro activity profile against other bacterial strains and in different antioxidant assays.
|
| ln Vivo |
Detailed in vivo activity data for 7-Hydroxy-4-methyl-8-nitrocoumarin are not extensively documented in publicly available literature. As a coumarin derivative with antibacterial and antioxidant activities, the compound is being investigated for its potential therapeutic applications. Further in vivo studies are needed to assess its efficacy and safety in animal models of bacterial infection or oxidative stress. The compound is primarily used as a research tool for studying the biological activities of coumarin derivatives.
|
| Enzyme Assay |
7-Hydroxy-4-methyl-8-nitrocoumarin is not typically used in standard receptor binding assays. Its antibacterial activity is assessed through standard antimicrobial susceptibility testing methods such as broth microdilution or agar disk diffusion assays. In these assays, bacteria such as Staphylococcus aureus and Escherichia coli are cultured in appropriate media and treated with varying concentrations of the compound. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth. Antioxidant activity is assessed using assays such as DPPH radical scavenging or FRAP assays.
|
| Cell Assay |
Cellular assays for 7-Hydroxy-4-methyl-8-nitrocoumarin are performed using bacterial cell cultures for antibacterial activity assessment. Bacteria are cultured in appropriate media and treated with the compound at varying concentrations. Bacterial growth is monitored by measuring optical density at 600 nm or by colony counting. For antioxidant activity, mammalian cell lines may be used to assess the compound's ability to protect cells from oxidative stress induced by hydrogen peroxide or other oxidants. Cell viability is assessed using standard assays such as MTT.
|
| Animal Protocol |
In vivo studies with 7-Hydroxy-4-methyl-8-nitrocoumarin are not extensively documented in publicly available literature. As a research compound with antibacterial and antioxidant activities, the compound may be evaluated in animal models of bacterial infection or oxidative stress. The compound would be administered via appropriate routes at defined doses, and efficacy would be assessed by measuring bacterial load, inflammatory markers, or oxidative stress markers. Further studies are needed to characterize its in vivo activity.
|
| ADME/Pharmacokinetics |
7-Hydroxy-4-methyl-8-nitrocoumarin has a molecular weight of 221.17 and a molecular formula of C10H7NO5. The compound has a logP of 1.8, one hydrogen bond donor, and five hydrogen bond acceptors. It has a rotatable bond count of 0. Detailed pharmacokinetic data for the compound are not extensively documented in publicly available literature. As a small molecule coumarin derivative, its absorption, distribution, metabolism, and excretion properties are subjects of ongoing research.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for 7-Hydroxy-4-methyl-8-nitrocoumarin are not extensively documented in publicly available sources. The compound is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and adherence to institutional biosafety and chemical hygiene guidelines. The compound is typically supplied as a light yellow to light brown solid powder.
|
| References | |
| Additional Infomation |
7-Hydroxy-4-methyl-8-nitrocoumarin is a functionalized benzopyrone derivative and a coumarin analog. It exhibits antibacterial activity against Staphylococcus aureus and Escherichia coli, as well as antioxidant activity. The compound's unique combination of hydroxyl, methyl, and nitro substituents on the coumarin core contributes to its biological activities. 7-Hydroxy-4-methyl-8-nitrocoumarin is used as a research tool for studying coumarin derivatives and their potential therapeutic applications. It is for research purposes only.
|
| Molecular Formula |
C10H7NO5
|
|---|---|
| Molecular Weight |
221.16628
|
| Exact Mass |
221.032
|
| CAS # |
19037-69-5
|
| PubChem CID |
5376327
|
| Appearance |
Light yellow to light brown solid powder
|
| Density |
1.521g/cm3
|
| Boiling Point |
402.5ºC at 760mmHg
|
| Melting Point |
254-259ºC(lit.)
|
| Flash Point |
197.2ºC
|
| Vapour Pressure |
4.69E-07mmHg at 25°C
|
| Index of Refraction |
1.648
|
| LogP |
2.238
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
359
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BGUBUSIGKOWDPO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7NO5/c1-5-4-8(13)16-10-6(5)2-3-7(12)9(10)11(14)15/h2-4,12H,1H3
|
| Chemical Name |
7-hydroxy-4-methyl-8-nitrochromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~22.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5214 mL | 22.6070 mL | 45.2141 mL | |
| 5 mM | 0.9043 mL | 4.5214 mL | 9.0428 mL | |
| 10 mM | 0.4521 mL | 2.2607 mL | 4.5214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
